Interim Report 2026
Filed with HKEX · Stock code 2591 · · 49 pages · English
Corporate Information 2 Financial Highlights 4 Management Discussion and Analysis 5 Corporate Governance and Other Information 21 Interim Condensed Consolidated Statement of 31 Profit or Loss Interim Condensed Consolidated Statement of 32 Comprehensive Income Interim Condensed Consolidated Statement of 33 Financial Position Interim Condensed Consolidated Statement of 34 Changes in Equity Interim C
Guangzhou Innogen Pharmaceutical Group Co Ltd on 6ix
Earlier from Guangzhou Innogen Pharmaceutical
- Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa
- Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
Later from Guangzhou Innogen Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- (1) Resignation of directors; and (2) change in composition of strategy committee
- List of directors and their roles and functions
- Voluntary announcement - appointment of senior management
Follow Guangzhou Innogen Pharmaceutical into a list and get an email when it puts out news.
Follow Guangzhou Innogen Pharmaceutical